Entheon Biomedical is a biotechnology company committed to the development of safe & effective psychedelic medicines in order to provide patients with access to evidence-based treatments for addiction disorders.
Why We Exist.
As evidenced by increasing rates of overdose deaths, societies all over the world have
found themselves ill-equipped and overburdened in managing and mitigating the
growing addiction crisis. More solutions are required to support and improve existing
recovery methods, in order to develop a treatment model rooted in innovation and
contemporary scientific findings.
Several of Entheon Biomedical’s founders have endured personal experiences with the loss of loved ones due to the absence of suitable treatment options for issues ranging from opiate addiction to treatment resistant depression. From this perspective, the Company’s core mission is to investigate, manufacture, and commercialize scientifically valid treatment options to address, ameliorate and treat the addiction crisis that is plaguing many of our very own families and the modern world at large.
"Entheon Biomedical believes that people suffering from life-inhibiting addiction disorders should have access to all scientifically-validated treatment protocols, and is committed to the development and commercialization of psychedelics that are FDA, EMA and Health Canada approved medicines designed to address the mounting public crisis of addiction and substance-related disorders."
- Timothy Ko, Entheon Biomedical’s CEO.
What is Entheon Studying?
Another differentiator is that British Columbia-based Entheon focuses on DMT, a hallucinogenic tryptamine drug and the main active ingredient in the plant medicine Ayahuasca.
“Psilocybin and DMT are both tryptamines and work on many of the same receptors in the human body, as they are molecularly very similar," Ko explained. "Much of the visual and emotional components of the experiences are similar, and it is possible to create psilocybin-like experiences with the appropriate dosing of DMT."
DMT is widely found in many plant and animal species, and even in the human brain. This makes it a safer drug, Ko said.
“The molecule is very well tolerated and metabolized in humans,” he said. “DMT is well-known to be short-acting and intense, but if properly harnessed and administered, the experience can be elongated and smoothed out to be less jarring, and result in a therapeutically useful experience.”
Values: Brand Story & Long-Term Value.
Entheon Biomedical is a psychedelic R&D company investing in research and an intensive drug discovery program with the aim to commercialize a portfolio of psychedelic therapies specifically designed for the treatment of addictive disorders. Psychedelics have a long history in the treatment of addictive disorders, and
we are all very excited to be working alongside a growing community of scientists and
medical professionals to dispel and overcome the many misconceptions with respect to
the clinical use of psychedelics.
Current scientific trials, combined with the wisdom of indigenous societies, and psychedelic research of the past, all point to a growing wealth of evidence legitimizing psychedelic substances as a medical and healing tool that has the potential to revolutionize the mental health sciences.
Entheon Biomedical is developing therapeutic formulations of psychedelic molecules that are designed to create different experiences in ways that will facilitate the healing process needed to resolve the underlying issues of addiction.
Corporate Social Responsibility.
Entheon Biomedical seeks to put aside a portion of funds it raises, and profits from its future operations, toward the preservation of the Amazon and the wisdom keepers of the region, so that they may continue their important traditions of medicine and healing.
- Addictions Crisis: Covid substance use/addiction issues and the need for healthier more effective for alternative mental health treatments
- DMT and its potential medical efficacy, what “analogs” mean in the context of psychedelics
- Financial Business News in Psychedelics
- Pharmaceutical / Drug Discovery/ Drug Development
- International Medical Research
- Investing in psychedelics, market opportunities
- Giving Back: Ensuring responsible investments in a hyperconscious market, CSR and the McKenna Academy project
- Cannabis, Plant Medicine, and mental health
Chief Executive Officer
Timothy Ko has a broad background of leading private ventures in the service sector, investor relations, retail and technology. Most recently, he served as Director of Hyperbridge Technology, a company focused on the development of decentralized technologies that facilitate crowdfunding. Mr. Ko’s passion for the psychedelic space and its potential for therapeutic use is shaped by firsthand knowledge of the shortcomings of the current mental health system and through his exposure to psychedelics, which he credits with saving his life. Following the loss of a loved one to a decades’ long fight with mental health and addictions, and through his personal experiences, Mr. Ko has committed himself to developing and providing further access to the lifesaving potential of psychedelic medicines.
Professor Matthew W. Johnson, Ph.D.
Matthew Johnson is a Professor of Psychiatry and Behavioural Sciences at Johns Hopkins, and an expert on psychoactive drugs and addiction. He is one of the world’s most widely published scientists on the human effects of psychedelics. Prof. Johnson
earned his Ph.D. in experimental psychology at the University of Vermont in 2004, and
has published over 110 peer-reviewed articles. Working with psychedelics for 16 years,
he published psychedelic safety guidelines in 2008, helping to resurrect psychedelic
Prof. Johnson was the 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association, and is the current President of the International Society for Research on Psychedelics. He has received continuous funding as a principal investigator for over 12 years.
Prof. Johnson has reviewed for over 75 scientific journals, and reviewed grants for the National Institutes of Health, National Science Foundation, the United States Military, and multiple governments outside of the United States and has presented his research in 13 nations. He has been interviewed widely by media including 60 Minutes, New York Times, Washington Post, Wall Street Journal, BBC, CNN, NPR, and Fox Business News.
Prof. Johnson and his research were featured in Michael Pollan's recent best-selling book, “How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence”.
Robin Carhart-Harris, Ph.D.
Dr. Carhart-Harris heads the Psychedelic Research Group within the Centre for Psychiatry at Imperial College, London, where he has designed a number of functional brain imaging studies with psilocybin (psychedelic mushrooms), LSD, MDMA and DMT, plus a clinical trial of psilocybin targeting treatment resistant depression. He has over 50 published papers in peer-reviewed scientific journals; two of which were ranked in the top 100 most impactful academic articles of 2016. Dr Carhart-Harris obtained his PhD in Psychopharmacology from the University of Bristol, and prior to that, an MA in Psychoanalysis at Brunel University. He has an honorary position at the University of Oxford.
Dr. Dennis McKenna
Dennis McKenna is an American ethnopharmacologist, research pharmacognosist, lecturer and author. He is the brother of well-known psychedelics proponent Terence McKenna and is a founding board member and the director of ethnopharmacology at the Heffter Research Institute. As advisor to Entheon, he brings with him decades of research and insight.
Christopher Timmermann, PhD.
Candidate, Scientific Advisor
Christopher Timmermann is a psychologist educated at the Catholic University of Chile with a Masters in Neuroscience and Neuropsychological Therapy from the University of Bologna. He is a PhD Candidate at the Centre for Psychedelic Research / Psychedelic Research Group, based at The Computational, Cognitive and Clinical Neuroimaging Laboratory (C3NL). His research focuses on the effects of DMT in the human brain.
Malin Vedøy Uthaug, Ph.D.
Completing her PhD at the department of Neuropsychology and Psychopharmacology, at the faculty of Psychology and Neuroscience at Maastricht University, The Netherlands, Malin investigated the short-term and long-term effects of ayahuasca and 5-MeO-DMT in naturalistic settings, while simultaneously initiating several other studies on the psychedelic substance mescaline and the breathing practice known as Holotropic Breathwork (HB). Malin is currently working as a Research Assistant at The Centre for Psychedelic Research, at Imperial College London, led by Dr. Robin Carhart-Harris. Here she is investigating the effects of 5-MeO-DMT on mental health related variables, brain activity and consciousness together with Christopher Timmermann, PhD candidate.
Besides being a researcher investigating psychedelics as a novel treatment option for mood-related disorders and trauma, Malin is also an editor for the ‘Journal of Psychedelics Studies’, a board member of the American podcast-show known as ‘Psychedelics Today’, and the co-founder of the Norwegian Association for Psychedelic Science (Norsk Forening for Psykedelisk Vitenskap [NFPV]) whose main aim is to educate the general public as well as researchers, and mental health practitioners in Norway about psychedelics.
Andrew Hegle, Ph.D.
Director of Operations
Dr. Andrew Hegle has been an adjunct professor of Pharmacology at the University of British Columbia since 2015. He has a background in molecular biology and biochemistry and has published research investigating the role of membrane receptor proteins in physiology, behavior and disease. Andrew’s main professional focus has been in the creation and management of laboratory operations. To that end, Andrew has held executive and operational management positions at several biotechnology companies, and was a cofounder of both Cannevert Therapeutics and Canalytic Laboratories in Vancouver. Dr Hegle has a long-held interest in the therapeutic potential of psychedelic medicine and is delighted to commit himself to furthering this field.
Christopher Gondi, Ph.D.
Chief Science Officer
Dr. Christopher Gondi is a Research Assistant Professor - Departments of Medicine, Surgery and Pathology at the University of Illinois, College of Medicine, Peoria. He is a professor of cancer biology and has extensive experience dealing with brain tumors and pancreatic cancer, for which the survival rates are very low.
Knowing firsthand the difficulty many face as they approach the end of their lives, Dr. Gondi seeks to explore the therapeutic benefits of psychedelics in helping patients reconcile their views and prepare for whatever exists beyond life. He also sees the transformative potential of these drugs in positively affecting the lives of those suffering from substance use disorders.
Yaron Eshel has 15 years of experience in Life Sciences innovation. Having led efforts in product development, regulatory compliance, and operations, Mr. Eshel has worked within start-ups as well as having consulted for them. Eshel has navigated the US, European, Israeli and Australian regulatory agencies including the registration of manufacturing facilities in the US, Central America, Israel and Australia to Good Manufacturing Practice levels. Mr. Eshel has led clinical trials in the US, Europe and Israel as well as worked with CRO’s all over the world.
Kenneth W. Tupper, Ph.D.
Advisor of Ethics
Kenneth W. Tupper served as an Adjunct Professor in the School of Population and
Public Health at the University of British Columbia, and has been active in the field of
psychedelic studies for more than fourteen years.
Having completed an M.A. thesis and Ph.D. dissertation that developed the concept of “entheogenic education,” a theoretical frame for understanding the kinds of learning that can be realized through the circumspect uses of psychedelics as cognitive tools. His other research interests include the cross-cultural and historical uses of psychoactive substances; public, professional and school-based drug education; and creating healthy public policy to maximize benefits and minimize harms from currently illegal drugs. Mr. Tupper is also currently a member of the Clinical & Scientific Advisory Board of the Multidisciplinary Association for Psychedelic Studies – Canada (MAPS-Canada) and the Advisory Board of the Wasiwaska Research Centre in Brazil.
Dr. Michael Walker
Dr. Walker received his pharmacology training at the University of London which
included a period of drug discovery training at Pfizer Ltd., (UK). Dr. Walker’s main focus has been in the discovery of drugs, both naturally occurring and synthetic, and he has
developed an expertise in traversing the path to successful drug discovery. Michael’s
commitment to the pharmaceutical/pharmacology industry includes 43 years of
instruction at UBC and numerous contributions to universities around the world. Over
the past 25 years, Dr. Walker was the founder or co-founder of eight different drug
discovery companies, both public and private, including Cardiome Pharma (TSX:COM)
in Canada and Verona Pharma Ltd. in London.
In addition, Dr. Walker has researched and published in numerous journals, periodicals and other publications, while presenting widely at conferences around the world.
Dana Nohynek, MSc.
Dana Nohynek is the director of regulatory affairs and quality assurance at the Canadian Institutes of Health Research. She holds a BSc (Honors) from the University of Waterloo (1998), a MSc from the University of Toronto (2000) and a RAC certification (2006) granted by the Regulatory Affairs Professionals Society (RAPS). She has over 10 years of industry experience that includes the development of regulatory strategies throughout various phases of clinical investigation, extensive interactions with regulatory authorities, preparation and submission of applications to health agencies in Canada, the United States and Europe. In addition, Ms. Nohynek has implemented quality systems, developed internal training programs and participated in agency audits. She has worked for small to mid-size biotech and medical device companies as well as with large pharma. She is an executive member of RAPS’s Southern BC chapter.
Evelina Rubinchik, Ph.D.
Preclinical, Regulatory Consultant
Evelina Rubinchik has over 25 years of industry and academic experience in drug development. She specializes in the creation of product development plans and liaises with the relevant regulatory authorities to ensure the acceptability of the plans. Throughout her career she has designed multiple pharmacokinetic studies, as well as spearheading pharmacokinetic and pharmacodynamic analyses. Ms. Rubinchik started her own successful consulting practice in 2009, focusing on nonclinical toxicology and pharmacology. She has worked with biotechnology companies in Canada, America and Asia. She holds a B.Sc & M.Sc in Biochemistry and a Ph.D in Pharmacology.
BioEnsemble LLC Drug, Development & Regulatory Consultants
BioEnsemble was established in 2006 and brings to all projects over 30 years of industry experience from leadership in small, medium and large pharmaceutical companies. Bioensemble has extensive experience in general management, business development, commercial strategy, product marketing, life-cycle management, clinical development, manufacturing and fundraising & financing. And has been involved in over 100 healthcare partnering discussions, valuations, due diligence and transactions and has developed and launched more than 20 brand products. If you have a moment, check out some of our recent media coverage: a feature article in Benzinga feature and an interview of CEO, Timothy Ko, by the emerging psychedelic publication DoubleBlind.